Marek Trněný, MD, PhD of the Charles University, Prague, Czech Republic gives a message on mantle cell lymphoma (MCL) to physicians and patients. Prof. Trněný’s first message to physicians is that it is worthwhile to manage patients comprehensively. This means, that we still use stem cell transplant but we also need to consider that we may be over-treating some patients. The second message is that we should try to understand and individualize patients based on their specific disease biology. For patients, his message is that the outcome has significantly improved over time.
Recorded at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA.